posted October 19, 2006 22:58 --------------------------------------------------------------------------------
AVVW :
Closed at .0115, had a couple days volume signal, today and 10/17 when volume was 4 / 5 times averages.
Has some problems though. The number one enemy of potential runners, the D word, DILUTION.
O/S : State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: As of October 16, 2006, we had 65,866,854 shares of common stock outstanding, $0.001 par value.
Like that it's oversold. I don't think I will offer more than .01. I see first resistance at .015, and more resistance, (if / when it gets by .015), at the terrible 2's, .02. Doubt if it gets by .015 with that kind of dilution staring at it.
The numbers had me excited, the O/S had me very excited, the SB-2 changed all that real quick. It could bounce for 40 or 50 %, but I would say it cannot sustain a decent run because of the 291M that need to be sold into the market.
Now pay attention. It might slip a bit lower, but it deserve serious watching because the numbers say it is right. I lkie it between .009 / .01, if / when it gets there. That 291M to be offered is a difficult thing to buy into, but I expect easily 25%, maybe 50% from the .01 area.
-------------------- A million seconds is 13 days. A billion seconds is 31 years.
IP: Logged |
posted
mm's took it down b/c it started to get away from them imo.. there was some nice buying all the way up to then.. this could be a huge breakout stock imo..
posted
Pretty much behaved like I thoguth it would. Bottomed two ticks over .01, bounced 40% and ARCA showed his ugly face all afternoon.
quote:Originally posted by will: I filled at .0102 :
will Member
posted October 19, 2006 22:58 --------------------------------------------------------------------------------
AVVW :
Closed at .0115, had a couple days volume signal, today and 10/17 when volume was 4 / 5 times averages.
Has some problems though. The number one enemy of potential runners, the D word, DILUTION.
O/S : State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: As of October 16, 2006, we had 65,866,854 shares of common stock outstanding, $0.001 par value.
Like that it's oversold. I don't think I will offer more than .01. I see first resistance at .015, and more resistance, (if / when it gets by .015), at the terrible 2's, .02. Doubt if it gets by .015 with that kind of dilution staring at it.
The numbers had me excited, the O/S had me very excited, the SB-2 changed all that real quick. It could bounce for 40 or 50 %, but I would say it cannot sustain a decent run because of the 291M that need to be sold into the market.
Now pay attention. It might slip a bit lower, but it deserve serious watching because the numbers say it is right. I lkie it between .009 / .01, if / when it gets there. That 291M to be offered is a difficult thing to buy into, but I expect easily 25%, maybe 50% from the .01 area.
-------------------- A million seconds is 13 days. A billion seconds is 31 years.
IP: Logged |
posted
The surge in volume happened during lunch hours, after that, no significant volume was noted: has this one been pumped by some group?
IP: Logged |
posted
doubt a group would play this one. doesn't really fit group criteria, IMO. It was ready to bounce, ARCA (used by the company to dilute?) killed the bounce run...
picked it up on a scan last week and didn't play it. might still bounce from here?
posted
WILL, great call, and great DD, I'd be surprised if they turn the dilution afterburners at a double bottom, but who knows. i have a different take on the situation though today. I think this thing started to take off, and some idiot wanted to dump some at profit and put in a MARKET order, rather than a limit, and mm's cooked them.. look at level 2.. it tells the story.. up until then there was NICE buying..
then as soon as that order went thru at .011 EVERYONE pulled there bid.. including me. the bid at that time was .012, lol.. im tellin you it was someone that got toasted on a market order, lol. then the bid came back and the ask got spanked eod. thinking that .011 order that went thru threw it all off lol.. mm's bought those .011 shares ..
I just missed those .0102 shares, will.. lucky dog, lol.. bit managed some at .012 and think those will be ok. i agree dilution sucks, but you have to remember they all dilute .. to a point. if they can produce great news and some plans, then pps will boom. If dilution is done properly and can be worked in with news then its ok.. wreckless dilution and toxic funding are always losers though. dont know anything for sure, we'll see. but i expect news.. good dd will..
posted
will, TA's use multiple mm's to dilute.. its not as clear cut as calling out arca as diluters. the reason it bounced is because it is extremly oversold. company cant dilute if there are no buyers. lol..
and at a double bottom buyers are exhausted.
look at the selling from plus .03 to these levels on that news.. the selling was overblown, and chances are mm's short big time on this.. this was at a 52 week high of .14 lol..
look at the massive selling all thru oct mm's just bought up shares...now they have to deliver imo..
Yeah watching the L2's today, ARCA was snipping the gonads on the ask for AVVW all day long at .014. DOMS jumped around on the bid accumulating shares at the bid for a good part of the morning. Probably won't see any significant movement in this hombre until ARCA has dumped his inventory.
IP: Logged |
posted
He might take a break and let us see .014 / .015 again ??? To wait for all 290M shares be a long long wait, they'll bounce it around, hopefully.
-------------------- A million seconds is 13 days. A billion seconds is 31 years.
IP: Logged |
posted
The only reason the Ask jumped a solitary tick from .0125 to .0126, is because ARCA moved out to .0139. He'll (or actually it), will be back at .0125 soon enough.
Anyone ever wonder why it is that ARCA seem to be the MM used when dilution is ocurring? ARCA isn't used ALL the time, but sure seems to be there often selling the Ask when dilution is going on.
I even said in my alert of 10/19 :
"Any gains will be held in check by the diluting MM selling his butt off on Ask, watch for ARCA."
Named the culprit days ahead of time.
-------------------- A million seconds is 13 days. A billion seconds is 31 years.
IP: Logged |
posted
lets hope you are apologizing for all the right reasons.. in that you were wrong about ARCA and dilution.. and a big run, lol..
will:
"My apologies guys.
Never saw it coming. Should have realized it smelled when they overdiluted past the 150M filed in the S8.
Tough business these pennies. Not only do you fight the MM manipulation and shorting, but you have to be on guard against the greedy, lying, diluting, CEO's.
posted
He's been there since open, and probably will be there most of the day. Isn't selling agressively, YET. Might move off and give us a little pop, but I wouldn't be greedy. Take profit, protect principle, and you can always play another day.
-------------------- A million seconds is 13 days. A billion seconds is 31 years.
IP: Logged |
posted
LUMBY, British Columbia, Oct 24, 2006 /PRNewswire-FirstCall via COMTEX/ -- AVVAA World Health Care Products, Inc. (AVVW), a biotech company offering global customers therapeutic skin and health care products, issued the following letter to its shareholders:
Dear Valued Shareholders:
With the end of calendar year 2006 just around the corner, avVaa World Health Care Products has implemented a number of directives that will impact our future growth plans and operating strategies as we move forward with full commercialization of our human and animal care product lines.
As an emerging growth company operating in a competitive industry such as ours, sufficient funding is crucial to the continued development and long-term success of our business model. Toward that end, avVaa recently secured a $2 million private placement funding, the proceeds of which are being used to further the Company's operating strategy and general corporate development purposes. The funding is in the form of convertible notes, at a 6% interest rate, which are convertible into common shares at a discount computed on a formula basis. As part of this financing transaction, the Company granted the investors 36 million share purchase warrants exercisable at a price of $0.16 per share. The details of the financing transaction are contained in the Company's financial statements available at http://www.sec.gov.
In recent months, avVaa has also added a number of new advisors to our Board of Directors to ensure continued leading-edge support for the completion of the Company's strategic business plan.
New advisor Dr. Mario Zamora, a well-respected healthcare specialist, has been studying the benefits of our NeuroSkin line of human skincare products for industry publication and presentation. Dr. Zamora recently instituted a Pilot Program in Houston, Texas, in conjunction with the Hispanic Health Institute, leading a sales and marketing campaign to secure additional sales for avVaa products, through advertising on major Spanish television and radio outlets for a period of six weeks. During that time, Dr. Zamora and avVaa's sales agents expect to explore direct sales potential for our products in Hispanic markets, as well as seek additional distributorships to introduce our products to this highly coveted market segment. Success in Houston will allow us to extend the program nationwide over the next several quarters. Product sales in conjunction with this campaign are expected to be forthcoming.
A veterinary specialist in dermatology and new advisor to the Board, Dr. Gene Nesbitt, has been working with management for some time in order to ensure avVaa's pet and equine care products are of the highest quality and effective for successful introduction to the growing pet and animal care products market throughout North America. Dr. Nesbitt has completed a number of studies on the benefits of our all-natural pet and equine care products and will be presenting his papers at a number of trade shows, veterinarian conventions and other planned industry events in the coming year.
While avVaa's board has grown in recent months, so have sales and marketing campaigns for both the Company's human and animal care product lines. Recent collaboration with AdSouth Partners, Inc. resulted in full-page print advertising placement in magazines nationwide with substantial readerships in our target market segments. A full-color brochure has also been completed for additional planned promotional activities. Our dedicated Customer Sales and Service Agents continue to support the strength of recent campaigns by filling orders as they arrive and maintaining customer relationships to facilitate continued sales and reorders.
Additional sales and marketing efforts planned in the coming weeks include test-marketing programs in targeted chain and independent stores in California and the Northwestern U.S. to ensure successful supply chain management and customer services are in place to handle large, upcoming projected sales. Upon pilot testing completion, expected within the next 60 days, chain and independent stores throughout the Northwest are expected to begin stocking NeuroSkin products for their customers.
In our primary healthcare products and services market, industry trade show events are an important part of successful market introduction for new products. Accordingly, we will attend a number of events to promote our products and present study findings to the industry's finest throughout North America this year, including attendance at the prestigious American Academy of Dermatology's 65th Annual Meeting in Washington D.C. this coming February.
In addition to our human healthcare products, we have also been working closely with bulk pet products suppliers to sell our products and are currently negotiating a possible 2007 re-branding (private labeling) of our Animal Care Products through a large, global pet products supplier. On the heels of recent successes in this marketplace, we will attend the most well respected animal and pet care products industry trade shows throughout the coming year.
In conjunction with trade show attendance and sales and marketing efforts, we are now sponsoring many local, regional and national pet and equine events throughout Canada and the U.S. These sponsorship programs have been an excellent resource to ensure product placement in the hands of our target consumers and allow us to promote our products at minimal costs. Additionally, a graphic artist has been retained to ensure colorful graphic designs for our entire line of animal and human products.
Finally, at our annual meeting this past July, the Board approved the appointment of a new auditing firm Davidson & Company LLP and the formation of an Audit Committee. As a result, avVaa's financial reporting process is now strengthened, as the Audit Committee, comprising two independent directors, reviews and approves annual and quarterly financial statements and regulatory filings. New auditors Davidson & Company LLP, the Company's accounting advisors Lancaster & David, Chartered Accountants, the Audit Committee and management have worked closely together to streamline the reporting process. As a result, for the first time in two years the Company has met its filing deadlines for quarterly reporting to the SEC.
Moving toward another year at avVaa, management remains committed to building value for its shareholders over the long-term and maintaining open communication along the way. We are excited about the positive consumer and retail responses to our products we have seen this year, for both human and animal care lines throughout North America, and will continue to concentrate our efforts on successful product placement and strategic sales and marketing.
We look forward to additional operational and product improvements to the benefit of our customers and shareholders in the coming months and pledge to continue Improving Quality of Life -- Naturally!
P.S.- Visit our newly redesigned website, created to support our latest advertising and marketing campaigns at: http://www.avvaa.com.
About avVaa World Health Care Products
avVaa World Health Care Products (AVVW) is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers. avVaa's patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin line of skin care products through mass, food and drug channels in the United States and globally.
"Finally, at our annual meeting this past July, the Board approved the appointment of a new auditing firm Davidson & Company LLP and the formation of an Audit Committee. As a result, avVaa's financial reporting process is now strengthened, as the Audit Committee, comprising two independent directors, reviews and approves annual and quarterly financial statements and regulatory filings. New auditors Davidson & Company LLP, the Company's accounting advisors Lancaster & David, Chartered Accountants, the Audit Committee and management have worked closely together to streamline the reporting process. As a result, for the first time in two years the Company has met its filing deadlines for quarterly reporting to the SEC.
Moving toward another year at avVaa, management remains committed to building value for its shareholders over the long-term and maintaining open communication along the way. We are excited about the positive consumer and retail responses to our products we have seen this year, for both human and animal care lines throughout North America, and will continue to concentrate our efforts on successful product placement and strategic sales and marketing."
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Smile]](smile.gif)
